

Anthera Pharmaceuticals Inc  
 Form 4/A  
 March 28, 2014

**FORM 4**

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION  
 Washington, D.C. 20549**

OMB APPROVAL

OMB Number: 3235-0287  
 Expires: January 31, 2015  
 Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person \*  
 TRUEX PAUL F

2. Issuer Name and Ticker or Trading Symbol  
 Anthera Pharmaceuticals Inc  
 [ANTH]

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

(Last) (First) (Middle)  
 25801 INDUSTRIAL BLVD SUITE B

3. Date of Earliest Transaction (Month/Day/Year)  
 03/25/2014

\_\_\_\_ Director  
 \_\_\_\_ Officer (give title below)  
 \_\_\_\_ 10% Owner  
 \_\_\_\_ Other (specify below)  
 President and CEO

(Street)  
 HAYWARD, CA 94545

4. If Amendment, Date Original Filed(Month/Day/Year)  
 03/27/2014

6. Individual or Joint/Group Filing(Check Applicable Line)  
 Form filed by One Reporting Person  
 Form filed by More than One Reporting Person

(City) (State) (Zip)

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Ownership (Instr. 4)
			Code	V	Amount or Price (A) or (D)		
Common Stock	03/25/2014		F		7,622 (1) \$ 3.3 (2)	D	9,333 (3)
Common Stock	03/25/2014		A		3,864 (4) \$ (5)	A	13,197 (3)
Common Stock	03/25/2014		F		1,352 (1) \$ 3.3 (2)	D	11,845 (3)
Common Stock	06/30/2013		A		6,250 (6) \$ 3.3	A	80,190 (3) (7)
						I	By Trust

Edgar Filing: Anthera Pharmaceuticals Inc - Form 4/A

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.**

SEC 1474  
(9-02)

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned**  
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)	7. Title and Amount of Underlying Securities (Instr. 3 and 4)	Amount or Number of Shares
Stock option (right to buy)	\$ 3.3	03/25/2014		A	18,440 (8)	03/25/2014 03/25/2024	Common Stock	18,440

## Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
TRUEX PAUL F 25801 INDUSTRIAL BLVD SUITE B HAYWARD, CA 94545			President and CEO	

## Signatures

/s/ Paul Truex                      03/28/2014

\*\*Signature of                      Date  
Reporting Person

## Explanation of Responses:

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Shares forfeited in lieu of payment of tax liability in connection with the vesting of 16,956 performance shares and 3,864 performance shares which represent the portion of the Reporting Person's 2012 and 2013 performance share awards.
- (2) The number of shares forfeited by the Reporting Person was based on the closing price of the Issuer's common stock on March 25, 2014, the vesting date of the 2012 and 2013 Grants.
- (3) Shares have been adjusted to reflect the Issuer's 1-for -8 reverse stock split effectuated July 15, 2013.
- (4) Award of Restricted Stock Units under the Issuer's 2013 Stock Option and Incentive Plan that vest immediately on March 25, 2014.

## Edgar Filing: Anthera Pharmaceuticals Inc - Form 4/A

- (5) Not applicable.
- (6) Shares acquired under the Issuer's 2010 Employee Stock Purchase Plan on June 30 2013.
- (7) This amended Form 4 is being filed for the purpose of correcting an incorrect Form 4 filed on March 27, 2014 reflecting ownership numbers that were pre-split. This corrects the numbers to reflect the Issuer's 1-8-reverse split effectuated July 15, 2013.
- (8) The Stock Option vests immediately on March 25, 2014.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.